2025

Alex's Lemonade Stand Foundation

Ewing Sarcoma Impact Report

Alex's Lemonade Stand
Foundation for Childhood Cancer™

AlexsLemonade.org

Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. By the time Alex passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a worldwide fundraising movement and the largest independent childhood cancer charity in the U.S. ALSF is a leader in funding pediatric cancer research projects across the globe and providing programs to families affected by childhood cancer.

With Gratitude

Dear Friend,

All of us at Alex's Lemonade Stand Foundation are sending a heartfelt thank you for supporting Alex's mission of curing childhood cancers like Ewing sarcoma through the discovery of new and safer treatments.

Your generosity empowers scientists to gather crucial preliminary data, publish breakthrough findings, and advance innovative treatment approaches. Because of you, we're moving closer to a future where no child faces Ewing sarcoma.

It's an honor to stand beside you in this fight. Your commitment fuels life-saving progress. If there's ever anything we can do for you, please let the ALSF team know.

Until there are cures,

Liz & Jay Scott
Alex's Parents & Co-Executive Directors
Alex's Lemonade Stand Foundation

ALSF

Thanks to Supporters Like You

73 **Ewing sarcoma projects (and counting) have been funded**

"ALSF funding was absolutely essential to make this project happen. There are not many funding instruments available to support projects of this scale."

— Dr. Florian Halbritter,
St. Anna Children's Cancer Research Institute

"Early career support for pediatric oncology physician-scientists is a critical lifeline during an incredibly vulnerable time in our careers. The support of ALSF has been and continues to be absolutely essential in making better therapies available faster for pediatric cancer patients."

— Dr. Leo Wang,
City of Hope

ALSF

Meet a **Ewing Sarcoma Hero**

Name: Cameron
Age: 12
Likes: Baseball, Roblox, the Philadelphia Eagles

After attending a community day event, Cam started complaining about a bug bite on his left upper leg. His parents figured some anti-itch cream would solve the problem, and then they went about their lives. Occasionally, he would complain about it, but Cam's parents figured it just needed time to heal. Instead, Cameron's lump, which he nicknamed Sparky, would not go away.

Fast forward and Cam's mom, Kristina, noticed a large lump on his leg where he thought he got bit. After an ultrasound, doctors confirmed it was a solid mass that should come out. Three days after his surgery, his parents heard the four words that would change their lives forever: "Your child has cancer." Through chemotherapy, surgeries and more, Cam never lost his smile.

Shortly after ringing the bell to celebrate no evidence of disease in May 2019, Cam was back on the baseball field and placed second in his very first wrestling tournament. He dreams of becoming a surgeon so he can help other kids with cancer.

ALSF gave Cam's family both community and hope: an invitation to meet former Eagles quarterback Carson Wentz remains a highlight of Cam's young life. Now 12 and cancer-free, he reminds newly diagnosed families that optimism and teamwork can turn fear into fight: one inning, one mantra ("Kick Sparky's butt!"), and one lemonade stand at a time.

Crazy 8 Award Research Update

Tracking Ewing Sarcoma Origin by Developmental and Trans-species Genomics



Heinrich Kovar, PhD, St. Anna Children's Cancer Research Institute

Dr. Heinrich Kovar and his team are working to understand how rare bone cancers like Ewing sarcoma begin, with the goal of creating better lab models to develop safer, more effective treatments for children. By studying how certain stem cells — normally meant to become bone, fat, or nerve tissue — can be disrupted by a gene called EWS-FLI1, the team is uncovering how these cells may revert to a more primitive, cancer-prone state. Using tools like single-cell analysis and zebrafish models, they've found that tumors may "remember" the type of cell they came from, helping to pinpoint when and where cancer is most likely to develop. This work could lead to new ways to target bone cancers early and more precisely, improving outcomes for young patients.

Research Spotlight New Project in Ewing Sarcoma

Elucidating the role of MIF in the immunosuppressive tumor microenvironment of Ewing sarcoma



Christopher Kuo, MD, Children's Hospital Los Angeles

For some pediatric cancers, recent progress has led to new treatments that use one's own immune system to target cancer cells. However, immunotherapy has not been successful for Ewing sarcoma because we don't understand how the tumor cells evade the immune system. Macrophage migration inhibitory factor (MIF) is a protein released by Ewing sarcoma and binds to immune cells, helping the tumor escape immune detection. The role of MIF in Ewing sarcoma and how it affects the surrounding microenvironment is not known. Thus, understanding MIF is crucial for uncovering how Ewing sarcoma evades the immune system. Dr. Kuo will focus on the role of Macrophage Migration Inhibitory Factor (MIF) in facilitating immune evasion in Ewing sarcoma. The long-term goal is to identify MIF as a novel therapeutic target to not only reduce treatment related toxicities for survivors but also to improve the treatment outcomes and responses for children with Ewing sarcoma in hopes of one day finding a cure.





Thank You

for all you do to help kids with cancer!